Neuland Laboratories reported a significant surge in revenue for Q2 FY26, reaching ₹516.1 crore, a 63.7% increase year-over-year. EBITDA soared by 138.8% to ₹156.9 crore, with a margin of 30.4%. The company’s PAT also witnessed substantial growth, reaching ₹96.5 crore. This strong performance was attributed to CMS commercial projects and increased operational leverage. Net debt stood at ₹(-6.6) crore.
Financial Performance Highlights
Neuland Laboratories announced robust financial results for Q2 FY26, demonstrating significant growth across key metrics:
- Total Income: Increased to ₹516.1 crore, up by 63.7% year-over-year.
- EBITDA: Reached ₹156.9 crore, a substantial increase of 138.8% compared to the previous year.
- EBITDA Margin: Improved significantly to 30.4%.
- PAT: Stood at ₹96.5 crore, reflecting a growth of 201.6% year-over-year.
H1 FY26 Performance Overview
The company also reported solid results for the first half of FY26:
- Total Income: ₹816.7 crore, a 7.5% increase year-over-year.
- EBITDA: ₹199.1 crore, a 2.5% increase year-over-year.
- EBITDA Margin: 24.4%.
- PAT: ₹110.2 crore.
Business Highlights
Key business updates from the announcement include:
- CMS revenues driven by commercial molecules.
- Growth in new projects orders which will be delivered over the course of this and next financial years
- In Prime segment Ezetimibe, and Mirtazapine were the key molecules. Ezetimibe likely to drive growth of the Prime segment.
- Specialty business subdued, revenue driven by sterile products.
Operational Achievements
The company also highlighted the following operational achievements:
- Unit-2 received EIR post FDA inspection in Q1 FY26.
- One USDMF filed in Q2 FY26.
- Unit-1 received Sword of Honour from the British Safety Council for outstanding Health & Safety practices.
Balance Sheet Metrics
Key balance sheet details as of September 2025:
- Shareholder’s Funds: ₹1,612.3 Cr
- Net Debt: ₹-6.6 Cr
- Tangible Assets: ₹822.3 Cr
- Working Capital: ₹690.8 Cr
Source: BSE
